H.C. Wainwright Maintains Buy on Esperion Therapeutics (ESPR) March 2026

H.C. Wainwright on March 10, 2026 maintained a Buy rating on Esperion Therapeutics, Inc. (ESPR). This ESPR analyst rating reiteration followed the company’s recent Q4 2025 results and a strategic update tied to the Corstasis acquisition. The firm also set a $16.00 price target, and the stock showed a -0.92% (-$0.02) intraday change on the announcement.